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[57] ABSTRACT 
Compositions containing as the active ingredient a spin 
trapping reagent, preferably ot-phenyl butyl nitrone (PBN) 
or spin-trapping derivatives thereof, in a suitable pharma 
ceutical carrier for administration to a patient are disclosed 
for treating or preventing symptoms associated With aging or 
other conditions associated With oxidative tissue damage. 
Other spin-trapping agents can also be used, such as 5,5 
dimethyl pyrroline N-oxide (DMPO) or ot-(4-pyridyl 
1-oxide)-N-tert-butylnitrone (POBN), and other spin 
trapping derivatives thereof. These compositions and meth 
ods are useful in the treatment of age-related disorders, 
pre-surgical and/or pre-anesthetic preparation or administra 
tion of chemotherapeutic agents, and in the treatment of 
disorders or trauma of the brain, cardiovascular system, and 
lymphatic system. Studies in animals demonstrate that 
administration of compound for a tWo Week period reduces 
the level of oxidiZed brain enzymes to normal and restores 
memory to the same level as tested in young control animals. 
135 Claims, 5 Drawing Sheets 
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METHOD OF TREATMENT OF 
CONDITIONS ASSOCIATED WITH 
OXIDATIVE TISSUE DAMAGE 
This is a continuation of application Ser. No. 08/365,548, 
?led Dec. 28, 1994, now US. Pat. No. 5,578,617, Which is 
a divisional of application Ser. No. 08/027,559, ?led Mar. 5, 
1993, now US. Pat. No. 5,405,874, Which is a continuation 
of application Ser. No. 07/589,177, ?led Sep. 27, 1990, noW 
abandoned, Which is a continuation-in-part of application 
Ser. No. 07/422,651, ?led Oct. 17, 1989, now US. Pat. No. 
5,025,032. 
BACKGROUND OF THE INVENTION 
The present invention is a method and compositions 
containing spin trapping agents for the treatment of age 
related dysfunctions and other conditions arising from oxi 
dative damage. 
Age related changes in central nervous system function 
have generally been associated With the loss of cells, a 
Widening of lateral ventricles and de?cits in short term 
memory. The precise mechanisms of functional changes as 
a result of aging, or other diseases associated With aging, 
have not generally been agreed upon. 
Several mechanisms for the generation of oxidiZed mate 
rial in the brain have been proposed. In particular, transition 
metals, especially iron and copper, have been suggested as 
mediating aspects of this oxidation. A marked reduction in 
certain neurotransmitter receptor systems has been associ 
ated With increased oxidation of proteins. For example, 
decreases in muscarinic receptors and other cholinergic 
systems have been characteriZed as they relate to alterations 
in functions in AlZheimers disease. It has also been hypoth 
esiZed that aging is associated With multiple minor periods 
of ischemia (multi-infarct conditions or transient ischemia 
attacks) Which, over a period of time, may give rise to the 
production of oxidiZed protein. 
Changes associated With ischemic brain disease have been 
proposed to be the result of alterations in calcium 
disposition, increase in excitoxic neurotransmitter release, 
production of free radicals and the attendant acidosis that 
results in an increase in the loosely related metals in the cell 
that are catalytic for the generation of oxygen free radicals. 
These changes are largely limited to neuronal elements. 
Reactive glia have been demonstrated, hoWever, they are 
mostly associated With postneuronal damage. 
The treatment of age related dementias have been largely 
limited by the inability to develop an appropriate model for 
the study of this condition. This is due to the fact that aging 
is a very complicated condition Which is dif?cult to model, 
especially With the lack of speci?c information associated 
With the functional and biochemical basis of human age 
related dementias. The use of animal models has largely 
depended upon model systems used in brain studies, Where 
the brains are not truly senescent, or the use of senescent 
animals, With little understanding of the origin of the senes 
cence or, in some cases, the inability to demonstrate truly 
functional senescence. 
The demonstration in a variety of systems, both neural 
and nonneural, that there is an age related enhancement of 
the level of oxidiZed protein in tissue gives rise to the 
possibility that age related dysfunctions in the central ner 
vous system may be associated With the build-up of oxidiZed 
proteins and oxidiZed macromolecules Within neurons 
throughout the central nervous system. The hypothesis is 
that cells Which have a buildup of oxidiZed protein are less 
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functional and less able to maintain the speci?ed role of 
those cells in that particular area of the central nervous 
system. While this hypothesis has been suggested by several 
investigators, there are no reports of substantial investiga 
tions in Which alterations in the oxidiZed protein burden of 
the central nervous system Was manipulated and correlated 
With a functional outcome on the part of the animal. Such an 
approach, if truly associated With brain dysfunction, Would 
provide a basis for reversing the age related neuronal de?cit 
of cells that are still viable. Thus, such an approach is 
targeted at cells Which are marginally functional but still 
viable. 
It is therefore the object of the present invention to 
provide composition and methods for the use in preventing 
or reversing age related functional de?cits. 
It is further the object of the present invention to provide 
composition and methods for use thereof Which are useful in 
preventing and reversing cognitive de?cits associated With 
infection or in?ammation. 
It is another object of the present invention to provide 
composition and methods reducing post traumatic cognitive 
dysfunction. 
SUMMARY OF THE INVENTION 
Compositions containing as the active ingredient a spin 
trapping reagent, preferably ot-phenyl butyl nitrone (PBN), 
or spin-trapping derivatives thereof, in a suitable pharma 
ceutical carrier for patient, are disclosed for treating or 
preventing symptoms associated With aging or other condi 
tions associated With oxidative tissue damage. The preferred 
PBN compositions have the folloWing general formula: 
H O' 
\ N/ 
/ +\ 
X Y 
Wherein: 
—/<OR>H 
X is phenyl or \ / , Wherein R is H, 
O 
0 
Z 1': Z CH—N/ — —, or ; or  , \ 
Y 
and n is a Whole integer from 1 to 5; or 
Y is tert-butyl group that can be hydroxylated or acetylated on 
one or more positions; phenyl; or 
OW / 
ll 
wherein W is—C—CH3, —NH—C—Z—, —C—OZ, or Z; and 
Z is a C1 to C5 straight or branched alkyl group. 
Other spin-trapping agents can also be used, such as 
5,5-dimethyl pyrroline N-oxide (DMPO) or ot-(4-pyridyl 
1-oxide)-N-tert-butyinitrone (POBN), and other spin 
trapping derivatives thereof. 
In the preferred embodiment, the compositions are admin 
istered one to tWo times daily by oral administration, at a 
6,107,315 
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dosage equivalent to between one and ten milligrams PBN/ 
70 kg of human body Weight. Studies in animals demon 
strate that administration of compound for a tWo Week 
period reduces the level of oxidiZed brain enZymes to 
normal and restores memory to the same level as tested in 
young control animals. A signi?cant reduction in oxidiZed 
proteins and memory recovery is observed as early as seven 
days after initiation of treatment; levels are still comparable 
to young controls one to three days folloWing cessation of 
treatment, and partially reduced at seven days folloWing 
cessation of treatment. 
These compositions and methods are useful in the treat 
ment of age-related disorders, pre-surgical and/or pre 
anesthetic preparation or administration of chemotherapeu 
tic agents, and in treatment of disorders or trauma of the 
brain, cardiovascular system, lymphatic system, and, 
potentially, in the treatment of some viral disorders charac 
teriZed by oxidation of host proteins in cells infected by the 
virus. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a graph of the alkaline protease activity from 
gerbil cortex (% of young, three to four month old gerbil 
cortex) for young gerbils (age three to four months), old 
gerbils (retired breeders of tWelve to ?fteen months of age), 
old gerbils that received tWice daily injections of 0.1 ml 
saline/kg body Weight, and old gerbils that received tWice 
daily injections of 10 mg PBN in saline/kg body Weight for 
tWo Weeks. Protease activity Was determined using oxidiZed 
protein extracted from young gerbil cerebral cortex. 
FIG. 2A and FIG. 2B are graphs comparing protein 
carbonyl activity (pmol/mg protein) (FIG. 2A) and 
glutamine synthetase activity (FIG. 2B) in the cerebral 
cortex (neocortex) of young adult and old gerbils over days 
of administration of 32 mg PBN/kg administered tWice a day 
for one, three, seven or fourteen days. At the end of each of 
the days indicated, animals Were decapitated and cerebral 
cortex removed and rapidly froZen in liquid nitrogen. Pro 
tein carbonyl content Was determined using the DNPH 
procedure. The results demonstrate the reduction in oxida 
tive damage to proteins and the loss of enZyme activity in 
gerbil cerebral cortex as a result of tWice daily administra 
tion of 32 mg PBN/kg (i.p.). Each histogram is the mean of 
three subjects. 
FIGS. 3A, 3B and 3C are graphs comparing changes in 
protein carbonyl (pnol/mg protein) (FIG. 3A), glutamine 
synthetase (FIG. 3B), and protease activity (% control) 
(FIG. 3C) over days folloWing termination of tWice daily 
dosing With 10 mg PBN/kg body Weight. FIG. 3A represents 
the level of carbonyl in the soluble protein obtained from 
gerbils treated for fourteen days and tested at 1, 3, 7 and 14 
days post dosing. FIG. 3B is the time related decrease in 
cortical glutamine synthetase (GS) activity after termination 
of tWice daily injections of PBN. FIG. 3C demonstrates the 
time related decrease in alkaline protease activity folloWing 
termination of tWice daily injections of PBN. Each histo 
gram is the mean 1 standard error of three subjects at 
each of the indicated times. The asterisk and dashed line 
indicates the old gerbil, untreated control values for each of 
the measures. 
FIGS. 4A, 4B and 4C are graphs comparing changes in 
protein carbonyl (pnollmg protein) (FIG. 4A), glutamine 
synthetase (FIG. 4B), and protease activity (% control) 
(FIG. 4C) over days folloWing termination of tWice daily 
dosing With 32 mg PBN/kg body Weight. FIG. 4A represents 
the level of carbonyl in the soluble protein obtained from 
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gerbils treated for fourteen days and tested at 1, 3, 7 and 14 
days post dosing. FIG. 4B is the time related decrease in 
cortical glutamine synthetase (GS) activity after termination 
of tWice daily injections of PBN. FIG. 4C demonstrates the 
time related decrease in alkaline protease activity folloWing 
termination of tWice daily injections of PBN. Each histo 
gram is the mean 1 SE. of three subjects at each of the 
indicated times. The asterisk and dashed line indicates the 
old gerbil, untreated control values for each of the measures. 
FIG. 5 is a graph of the eight arm radial arm maZe 
performance of young or old gerbils treated With either 
saline or PBN. Gerbils Were placed into the central com 
partment of the maZe With the barrier in place to limit 
exploration. After the barrier Was removed, the number of 
arms re-entered and the total elapsed time before all eight 
arms Were entered Was recorded. Each histogram represents 
the mean 1 of 18 gerbils. The animals Were administered 
PBN tWice daily (either 10 or 32 mg PBN/kg body Weight) 
for seven days and tested at the end of seven days of dosing. 
DETAILED DESCRIPTION OF THE 
INVENTION 
It has noW been discovered that, further to the methods 
using PBN for the treatment and prevention of ischemic 
damage described and claimed in US. Ser. No. 07/422,651 
?led Oct. 17, 1989, noW Reissue US. Pat. No. 35,112, 
spin-trapping agents are useful in preventing or treating 
symptoms associated With aging, trauma, drug administra 
tion and surgery, especially of the brain. As used herein, a 
free radical scavenger or spin-trap reagent is a molecule that 
Will form a stable complex With free radical. A free radical 
carbon trap is a molecule in Which the free radical is 
localiZed on a carbon atom or a nitrogen atom. As a result 
of this chemical bond formation, the free radical is no longer 
damaging to the cell. In combination With a pharmaceutical 
vehicle suitable for administration to a patient, preferably by 
oral administration, these compounds are useful in prevent 
ing or reversing symptoms associated With aging, for 
example, increased levels of oxidiZed proteins, decreased 
enZymatic activity, and spatial and short term memory. 
Currently, there are no effective, non-toxic treatments for 
aging. Effectiveness has been demonstrated in animals after 
as feW as seven days of administration. Effectiveness con 
tinues for at least one Week after administration. Values 
return to pretreatment levels after tWo Weeks. 
USEFUL SPIN-TRAPPING COMPOUNDS 
PBN and Derivatives Thereof. 
The preferred spin-trapping compounds are ot-phenyl 
t-butyl nitrone (PBN), and derivatives thereof. PBN has no 
measurable effect on normal or uninjured cells. PBN is the 
preferred compound at this time, although a number of 
derivatives are also useful, including hydroxy derivatives, 
especially 2-, 3- or 4-hydroxy PBN and mono-, di- and 
trihydroxy tert-butyl nitrone; esters, especially esters Which 
release 2-, 3, or 4-hydroxyphenyl t-butyl nitrone such as the 
acetoxy derivative, 2-, 3-, or 4-carboxyphenyl t-butyl 
nitrone, such as the ethyl derivative, or phenyl hydroxybutyl 
nitrone, such as the acetoxy derivative; alkoxyl derivatives, 
especially alkoxyl derivatives Which release 2-, or 
4-hydroxyphenyl t-butyl nitrone, such as the methyl deriva 
tive; and acetamide derivatives, especially acetamide deriva 
tives Which release 2-, or 4 aminophenyl t-butyl nitrone, 
such as the acetyl derivative; diphenyl nitrone (PPN) and the 
analogous diphenyl nitrone derivatives. As used herein, 
“PBN” refers to both phenyl t-butyl nitrone and derivatives 
thereof, unless otherWise stated. 
6,107,315 
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The general formula for PBN and useful derivatives 
thereof is: 
Wherein: 
—/ (OR)H 
X is phenyl or \ / , Wherein R is H, 
and n is a Whole integer from 1 to 5; or 
Y is tert-butyl group that can be hydroxylated or acetylated on 
one or more positions; phenyl; or 
OW / 
Wherein W is C—CH3, —NH—C—Z, C-OZ, or Z; and 
Z is a C1 to C5 straight or branched alkyl group. 
Other Spin-Trapping Reagents. 
Other spin-trapping agents can also be used, such as 
5,5-dimethyl pyrroline N-oxide (DMPO) or ot-(4-pyridyl 
1-oxide)-N-tert-butylnitrone (POBN), and spin-trapping 
derivatives thereof. Derivatives are made using standard 
techniques, for example, for substitution of the methyl 
groups. The general formula for DMPO is: 
A / 
B i 
0 
wherein A and B are independently CH3, CHZOH, 
(OWL. 
CHZOW, or 
n is an integer from 1 to 5 
wherein W is 
—C—OZ, or Z; and 
Z is a C1 to C5 straight or branched alkyl group. 
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The general formula for POBN is: 
O 
HC=N—Y 
/ 
\ | 
/ N 
S i 
O 
Wherein 
Y is a tert-butyl group that can be hydroxylated or acetylated 
on one or more positions; phenyl; or 
/OW 
O 
II 
—C—OZ, or Z; and S=H, (OR)n, Wherein R is H, 
n is a Whole number from 1 to 4, or 
Z is a C1 to C5 straight or branched alkyl group. 
Indications that the compositions are useful in treating. 
The free-radical scavenger compositions are useful in 
treating a variety of dysfunctions or disorders characterized 
by oxidiZed proteins in the tissues or cells. Oxidation of 
cytosolic protein has been demonstrated to occur in a Wide 
variety of pathological conditions. Accordingly, compounds 
Which have as their fundamental mechanism of action the 
interference of production of oxidiZed protein should be 
useful in the treatment of a Wide variety of diseases having 
What appears at ?rst glance to be Widely dissimilar 
etiologies, because the fundamental cause of the condition is 
oxidation of protein or nucleic acids. 
In one embodiment, the spin-trapping agent is adminis 
tered to a patient to reverse the damage occurring as a 
function of age. Preliminary results indicate that there is a 
net increase in the oxidation of proteins and the accumula 
tion of oxidiZed material in the brain. The development of 
senil plaque is also routinely observed in aged patients. 
Other disorders are those resulting from trauma, such as 
a bloW to the head, or from drug treatment, for example, 
administration of anesthesia or drug abuse, or even as a 
result of some types of viral infections. 
It has noW been determined that the level of oxidiZed 
brain protein appears to be inversely related to performance 
in a short term memory task and directly related to risk of 
stroke-induced damage and behavioral change. Increased 
cellular oxidation may result in one or more of the folloW 
ing: (a) oxidative damage to cellular proteins could cause a 
6,107,315 
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change in the regulation of ion channels, there could be a 
change in the rate and ef?ciency of signal translation and 
membrane depolarization, signi?cant changes in energy 
?uxes may occur and compromise selective function, the 
?delity of RNA transcription may be altered due to oxidative 
damage to DNA, RNA translation may be affected either by 
oxidation of the RNA or regulatory macromolecules, or the 
rate of protein degradation may be altered. 
Any of these changes could negatively impact on the 
acquisition consolidation and retrieval of information, even 
by interference With a single step in the learning and 
memory process. It is possible that oxidation of cells in a 
particular brain region could result in acquisition de?cits, 
Whereas oxidation of a different region could result in output 
de?ciency. Considering the number of devastating neurode 
generative diseases, including AlZheimer’s disease, this 
treatment could potentially be a tremendous help to people 
With these disorders. 
Examples of other disorders that can be treated With these 
compositions include peripheral neuropathy of diabetes, 
exercise induced muscle damage and pain, and enhancement 
of cellular response to hormonal signals. 
Treatment of Neurodegenerative Disorders. 
Several neurodegenerative conditions are most appropri 
ately treated by compounds that interfere With protein oxi 
dation. AlZheimer’s disease has been associated With the 
accumulation of abnormal oxidiZed proteins or the produc 
tion of abnormal proteins in areas that are pathologically 
affected. In addition, age related enhancement in protein 
oxidation occurs in all cells in the aged individual. PBN and 
derivatives thereof have been demonstrated to be useful in 
the reduction in protein oxidation and in the increase in the 
activity of critical enZymes Within the brain of aged animals. 
Since this is a fundamental change in oxidative state, it is 
likely that PBN and other related compounds Would be 
useful When given chronically to individuals Who are in the 
early phases, or possibly in the late phases, of AlZheimer’s 
disease. In addition, multi-infarct dementias should be treat 
able With these compounds, since they also deal With 
ischemia reperfusion oxidation issues. 
Senile dementia has not been directly evaluated for 
ischemia reperfusion etiology or protein oxidation, hoWever, 
it is likely that senile dementia Would also be treatable With 
these compounds. This is based on the hypothesis that 
advanced age is associated With increased production of 
oxidiZed protein. In progeria, a unique condition in Which 
aging is accelerated, Stadtman and colleagues at the NIH 
have demonstrated that there is a marked increase in the 
base-level of oxidiZed protein even in young adult subjects 
With progeria, as reported by Oliver, et al., J. Biol. Chem. 
262, 5488—5491 (1987) and Starke-Reed and Oliver,Arch. 
Biochem. Biophys. 275, 55 9—567 (1989). While this is a rare 
condition it should also be treatable With these composi 
tions. 
Another condition Which is likely to be associated With 
oxidative damage arising from microcirculatory dif?culties 
is the diabetic peripheral neuropathies and vascular change. 
These are tragic conditions in Which amputation is eventu 
ally necessary in order to save the patient. While these 
compounds are not likely to improve vascular How they are 
likely to reduce the impact of transient changes in vascular 
?oW Which result in oxidation and damage to the peripheral 
nerves and also in damage to the skeletal muscle Which is 
often associated With the condition called exercise induced 
or intermittent claudication. If the retinopathy associated 
With diabetes is also an ischemia reperfusion microcircula 
tion problem, then the spin-trapping compounds Will be 
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useful in treating the retinal damage Which occurs very 
frequently in diabetic patients. 
Pre-Surgical Preparation. 
Since the status of the cell and its survival in a hypoxic or 
anoxic environment is dependent upon the ability of the cell 
to compartmentaliZe metals and handle oxygen in a useful 
manner, in contrast to peroxidation, it is expected that these 
compounds Will be useful as presurgical preparatory medi 
cation to reduce the carbonyl load and improve the enZyme 
status of the patient prior to elective surgery. These com 
pounds Would also help the cells of the body achieve a 
higher level of enZymatic function, shorten the recuperative 
phase, and reduce the likelihood of any interoperative com 
plications associated With changes in microcirculation. 
Treatment of Viral Infections and In?ammatory Disor 
ders. 
Retroviruses selectively infect certain types of cells, such 
as lymphocytes. An example of a retrovirus that has been the 
subject of much research activity is the human immunode 
?ciency virus (HIV), Which causes Acquired Immunode? 
ciency Syndrome (AIDS). No means for prevention of 
infection has been found, although there have been numer 
ous attempts to ?nd a treatment. Since activation of lym 
phocytes is associated With the oxidation of protein and 
activation of lymphocytes is required prior to release of 
neWly formed viruses, it is expected that administration of 
these compositions Will inhibit infection and replication of 
lymphocytes by the viruses. The activation of the T-4 
lymphocyte is associated With a cascade of biochemical 
intracellular changes, one of Which is the production of 
oxidiZed protein. If PBN related compounds can block 
protein oxidation in the abnormal process then it is possible 
that PBN or other spin-trappin compounds could in fact 
interfere With the process of viral replication and/or dissemi 
nation of the virus from the host cell (T-4 lymphocyte), 
thereby acting as a virustatic agent by preventing the T-4 
lymphocyte from releasing the neWly formed viruses. This 
Would be analogous to the use of isoniaZid (INH) in the 
treatment of tuberculosis. At loW doses INH is a tubercula 
static in that it reduced the infectivity and spread of the 
tuberculosis, thereby effectively protecting the patient from 
pulmonary damage. 
It is important to note that the effects of the spin-trapping 
compounds occur in animals that have a base-level of 
carbonyl formation Which appears to be necessary for post 
translational processes. Old animals have a signi?cantly 
elevated level of carbonyl protein Which is associated With 
decreased enZymatic function relative to young control 
animals. When young control animals are given the exact 
same dosage regimen, there is no signi?cant change in 
enZyme activity nor is there signi?cant change in protein 
carbonyl. Thus the PBN and related spin-trapping com 
pounds are not likely to interfere With fundamental pro 
cesses that are necessary for the normal cellular function. 
In conclusion, a number of clinical conditions appear to 
have as their fundamental cause oxidation of cellular protein 
and enZymatic damage. Spin-trapping compounds are effec 
tive in animal models in reducing the protein oxidation and 
improving enZymatic function. This occurs in preparations 
in Which the abnormal oxidiZed protein is modi?ed and 
protected but the normal post translational oxidation is 
alloWed to occur. This Would suggest that PBN does not 
interfere With the normal necessary oxidation of proteins 
folloWing synthesis. 
Effective Dosages of PBN. 
Exemplary dosages of PBN range from 0.1 to 10 mg/kg 
of body Weight in animals. The effective dosage of PBN in 
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humans is expected to be between approximately 1 and 10 
mg/70 kg body Weight. Toxicity tests have demonstrated that 
the compound is completely innocuous, With such loW 
toxicity that it Was not possible to determine an LDSO. 
In the preferred application, the PBN is administered to a 
patient suffering from memory loss or other symptoms 
frequently associated With aging. Optimum results are gen 
erally observed after tWo Weeks of daily or tWice daily oral 
administration. The compositions can also be effectively 
administered prior to, during or shortly after surgery, and 
prevent or decrease the extent of cellular damage resulting 
from either the trauma or anesthesia. 
Since the trapping of endogenous free radicals is speci?c 
for only those cells that have been exposed to the conditions 
that result in the production of free radicals, the traps have 
little or no effect on normal cells. The bene?cial effects 
occur only in injured cells, and do not require the presence 
of speci?c receptors, speci?c enZymes, and/or speci?c cell 
types. 
Methods of Administration of PBN. 
The PBN is preferably administered systemically, most 
preferably orally, since this is the most rapid and ef?cient 
means for delivering the active compound to the site of free 
radical generation. The PBN may be administered at once, 
or may be divided into a number of smaller doses to be 
administered at varying intervals of time. Other methods of 
administration can also be used, including subcutaneous, 
intravenous, and intraperitoneal administration. The concen 
tration of active compound in the drug composition Will 
depend on absorption, inactivation, and excretion rates of 
the drug as Well as other factors knoWn to those skilled in the 
art. The effective dosage may also be determined based on 
that amount required to prevent or reverse predisposition of 
the cells to damage resulting from depletion of ATP (as 
demonstrated by in vivo NMR) and damage from free 
radical generation. It is to be noted that dosage values Will 
also vary With the condition of the patient being treated. It 
is to be further understood that for any particular subject, 
speci?c dosage regimens should be adjusted over time 
according to the individual need and the professional judg 
ment of the person administering or supervising the admin 
istration of the compositions, and that the concentration 
ranges set forth herein are exemplary only and are not 
intended to limit the scope or practice of the claimed 
composition. 
A preferred mode of administration of the active com 
pound is in a form for oral delivery. Oral compositions Will 
generally include an inert diluent or an edible carrier. 
Preferred pharmaceutical carriers for intravenous adminis 
tration are saline or phosphate buffered saline at physiologi 
cal pH. Since PBN degrades at pH less than approximately 
3 to 4, it is preferred to administer the PBN at a pH of 4 or 
higher, or in combination With food, a buffering agent, or in 
an enteric coating. For oral delivery, the PBN may be 
enclosed in capsules, compressed into tablets, 
microencapsulated, entrapped in liposomes, in solution or 
suspension,alone or in combination With a substrate immo 
biliZing material such as starch or poorly absorbable salts 
such as immodium. Pharmaceutically compatible binding 
agents can be included as part of the composition. The 
tablets or capsules may contain, for example, any of the 
folloWing ingredients, or compounds of a similar nature: a 
binder such as microcrystalline cellulose, gum tragacanth or 
gelatin; an excipient such as starch or lactose, a disintegrat 
ing agent such as alginic acid, Primogel®, or corn starch; a 
lubricant such as magnesium stearate or Sterotes; a glidant 
such as colloidal silicon dioxide; a sWeetening agent such as 
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sucrose or saccharin; or a ?avoring agent such as 
peppermint, methyl salicylate, or orange ?avoring. When 
the dosage unit form is a capsule, it can contain, in addition 
to material of the above type, a liquid carrier. In addition, 
dosage unit forms can contain various other materials Which 
modify the physical form of the dosage unit, for example, 
coatings of sugar, shellac, or other enteric agents. 
The present invention Will be further understood With 
reference to the folloWing non-limiting examples demon 
strating methods for determining effectiveness of PBN 
administration for treatment or prevention and/or reversal of 
symptoms associated With aging. 
EXAMPLE 1 
Determination of Brain EnZyme Levels in Old 
Versus Young Gerbils Treated With PBN 
Acorrelations betWeen the duration of ischemia and either 
the change in spontaneous behavior or the level of oxidiZed 
brain protein has previously been demonstrated in gerbils. 
Many other psychiatric and neurological conditions have 
been proposed to be the result of oxidation. Among these 
conditions, cellular aging has been associated With oxygen 
radicals and the accumulation of proteins. The level of 
oxidiZed protein, glutamine synthetase activity, brain pro 
tease activity and radial arm maZe performance in young 
adult and retired breeder gerbils have noW been compared 
and demonstrate that there is a direct relationship betWeen 
the age of the subject and the level of oxidiZed brain protein, 
as measured using a protein carbonyl assay. Increased levels 
of protein carbonyl Were associated With decreased 
glutamine synthetase activity and decreased alkaline pro 
tease activity. In contrast, there Was no change in acid 
protease activity of retired breeders, compared to young 
adult gerbils. Consistent With the age-related increase in 
protein oxrdation and enZyme damage, retired gerbils made 
signi?cantly greater numbers of errors in a test of short-term 
memory, compared to young adult gerbils. These studies 
demonstrate that the functional de?cits that occur as a result 
of aging may be associated With increased protein oxidation 
and decreased brain enZyme activities. 
This system has been used to demonstrate the effective 
ness of PBN in restoring young brain enZyme levels and 
short term memory to old animals. The results are shoWn in 
FIGS. 1 through 5, as folloWs. Young gerbils Were obtained 
from Tumblebrook Farms, West Brook?eld, Mass., Weigh 
ing 50—60 grams and age three to four months. Control 
gerbils Were given saline. Animals Were killed by decapita 
tion and their brains removed for analysis. 
FIG. 1A is a graph of the percent alkaline protease in 
young (three to four month old) gerbils, old (tWelve to 
?fteen month old retired breeder) gerbils, old gerbils admin 
istered 0.1 ml saline tWice daily (b.i.d.), and old gerbils 
administered 10 mg PBN/kg body Weight bid. for fourteen 
days. 
The results demonstrate that PBN is effective in restoring 
alkaline protease levels in old animals to those levels present 
in young animals. 
FIG. 2A is a graph of the changes in protein oxidation 
from brains of young and senescent gerbils, plotting nmol 
protein carbonyl/mg protein versus days of treatment With 
PBN. The gerbils Were given tWice daily injections of 32 
mg/kg PBN for fourteen days. Animals Were killed at one, 
three, seven and fourteen days and protein carbonyl levels 
determined. 
As can be seen in the ?gure, there is no change in the level 
of oxidiZed protein of young gerbils treated for up to 14 days 
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With PBN. This indicates that the level of oxidized protein 
is likely to be a natural and necessary post translational 
effect, for example, if after synthesis of the protein, the 
protein is activated by a modi?cation involving carbonyl 
oxidation. In contrast to the carbonyl level seen in young 
animals, control aged animals (15 months of age) have a 
marked increase of carbonyl content. This increased carbo 
nyl content is responsive to treatment With PBN. Multiple 
days of treatment With PBN results in a progressive reduc 
tion in the level of protein carbonyl to the level seen in 
young animals. 
The level of protein carbonyl reduction (oxidiZed protein 
burden of neurons in the brain) is only to the level of the 
normal young gerbil brain. Neither the levels in the young 
gerbil brain nor the levels in the senescent gerbil brain can 
be further reduced beyond this level. This observation 
supports the hypothesis that there is a necessary level of 
oxidation that occurs in cells in normal animals, Which is 
required for cells to have “normal function”, and that control 
aged animals (15 months of age) have a marked increase of 
carbonyl content. This increased carbonyl content is respon 
sive to treatment With PBN, The ability of PBN to reduce the 
protein carbonyl load of cells also indicates that this is an 
active oxidation process Which occurs at a regular or pre 
dictable rate and that there are mechanisms existent Within 
the cells of the brain Which can remove this oxidiZed protein 
if the process is interrupted. 
FIG. 2B compares the levels of glutamine synthetase (gs) 
in young and old animals and evaluates the effects of daily 
administration of PBN on the speci?c activity of the 
enZyme. This particular enZymatic marker has been selected 
because it is a highly sensitive protein to oxidation and 
because it is a metalloprotein that has bound to it metal 
Which may participate in the generation of free radicals if the 
metal is dissociated With its binding site. Glutamine syn 
thetase activity has been used by Stadman and colleagues 
(Oliver, et al., Proc. Natl. Aca'. Scie. USA 87, 5144—5147 
(July 1990)) as a marker enZyme for alterations folloWing 
protein oxidation. 
As shoWn in FIG. 2B, the level of glutamine synthetase is 
loWer in old gerbils (1.2) than in young adult gerbils (2.1). 
This is consistent With previous studies in Which increases in 
the level of the carbonyl protein (oxidiZed protein in cells) 
is associated With a decrease in glutamine synthetase activ 
ity. In particular, if the glutamine synthetase enZyme is 
puri?ed and the carbonyl content of that enZyme is 
evaluated, there is a marked increase in the level of oxidiZed 
protein in the presence of loWered glutamine synthetase 
activity. As also demonstrated in FIG. 2B, repeated admin 
istration of PBN in young gerbils had no effect on glutamine 
synthetase activity, providing further evidence that the level 
of carbonyl is associated With normal function and chronic 
administration of PBN has no effect on either the level of 
carbonyl or on the marker enZyme activity. In contrast to the 
young gerbils, old gerbils given daily injections of PBN 
shoW a time related increase in glutamine synthetase activity 
that parallels the reduction in protein carbonyl content, 
indicating that the reduction in oxidiZed protein burden of 
cells is associated With a recovery of the enZymatic activity 
to the normal level seen in young adult gerbils. 
It is important to note that there is no increase in enZy 
matic activity above that seen in young adult gerbils. Thus 
the treatment With PBN reverses the effect of aging on 
enZymatic activity but does not result in an activation of 
enZyme activity that exceeds the normal values. 
EXAMPLE 2 
Determination of Residual Effect of PBN on 
Reduction of Brain EnZyme Levels 
As shoWn in FIGS. 3A, 3B, and 3C, as compared With 
FIGS. 4A, 4B, and 4C, administration of 10 mg PBN/kg is 
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as effective as administration of 32 mg PBn/kg body Weight 
in restoring young enZyme levels. The appropriate dosages 
and full range of effective dosages for other species of 
animals can be determined using a similar methodology. 
The time related changes in protein oxidation and enZyme 
activity folloWing termination of tWice daily dosing With 
either 10 mg PBN/kg (FIGS. 3A, B, and C) or 32 mg 
PBN/kg (FIGS. 4A, B, and C) are also shoWn by these 
?gures. The results demonstrate that the effect of the PBN is 
unaltered one to three days after termination of treatment 
tWice daily With the PBN, although the PBN itself has a 
half-life of three hours. At seven days, the enZyme levels are 
altered by approximately 50%. 
At fourteen days, the oxidiZed enZymes have returned to 
approximately their pre-treatment levels. 
EXAMPLE 3 
Demonstration of Correlation BetWeen Effect of 
PBN on Brain EnZymes and Memory 
FIG. 5 demonstrates that there is a functional counterpart 
to such treatment. Young and old gerbils Were tested in a 
radial arm maZe test for spacial and short term memory. 
Animals Were placed in the central hub of a eight armed 
radial maZe and given access to explore all eight arms of the 
radial arm maZe. When the animal completed the test of 
exploring each of the eight arms, the animal Was removed 
from the maZe. The number of times that the animals 
reentered arms that had been previously entered Was counted 
as an error. Under ideal conditions animals Will enter each 
one of the eight arms but not reenter any of the arms. In 
many cases young adult gerbils (young) entered each of the 
arms Without reentering any of the arms. The time required 
to enter all eight arms Was also recorded but did not appear 
to determine the efficiency of the short term memory task. As 
can be seen in FIG. 5, young gerbils made an average of 2.83 
errors during the test session. In contrast old gerbils made an 
average of 6.82 errors, Which is a highly signi?cant differ 
ence betWeen the tWo groups. 
Young adult gerbils exposed to a period of transient 
ischemia, Which is also an oxidiZing process, make a sub 
stantial number of errors With an average value of 15 errors 
in such a test session. During the post ischemic period, there 
is a marked build up of carbonyl protein and reduction in 
glutamine synthetase activity similar to that Which is seen in 
aging. 
Treatment of gerbils for seven days results in a marked 
alteration in the number of errors seen With old gerbils. 
Young gerbils given PBN for seven days Were not signi? 
cantly different from control gerbils Whereas the old gerbils 
given PBN for seven days shoWed a marked reduction in the 
number of errors and returned to the range of performance 
seen With control young gerbils. Thus, there is a functional 
counterpart to the biochemical changes that are seen in that 
reduction in protein carbonyl and the increase in glutamine 
synthetase activity folloWing chronic PBN treatment. This 
functional counterpart is demonstrated by the number of 
errors seen in a short term spacial memory task, the radial 
arm maZe. It should be noted that the radial arm maZe test 
does not require any food reinforcement or any other reWard 
associated With the test. Naive animals are placed into the 
radial arm maZe, are tested once and these differences are 
reliable on retest. 
Modi?cations and variations of the method and compo 
sition for the treatment of aging Will be obvious to those 
skilled in the art from the foregoing detailed description. 
6,107,315 
13 
Such modi?cations and variations are intended to come 
Within the scope of the appended claims. 
We claim: 
1. A method of treating peripheral neuropathy in a patient 
suffering from peripheral neuropathy comprising adminis 
tering to a patient an effective peripheral neuropathy treating 
amount of a composition having as the active agent a 
compound selected from the group consisting of alpha 
phenyl t-butyl nitrone (PBN); 5,5-dimethyl pyrroline 
N-oXide (DMPO); alpha-(4-pyridyl 1-oXide)-N-tert 
butylnitrone (POBN) and derivatives thereof selected from 
the group consisting of hydroXy PBNs, POBNs and 
DMPOs; PBN, POBN and DMPO esters; acetoXy PBNs, 
POBNs and DMPOs; alkyl PBNs, POBNs and DMPOs; 
alkoXy PBNs, POBNs and DMPOs; and phenyl PBNs, 
POBNs and DMPOs having spin trapping activity in vivo in 
tissue; and 
a pharmaceutically acceptable carrier therefor. 
2. The method of claim 1 Wherein the active agent is PBN. 
3. The method of claim 1 Wherein the active agent is 
provided in a dosage of betWeen 1 to 300 mg/kg body 
Weight. 
4. The method of claim 1 Wherein the active agent is 
provided in combination With a pharmaceutical carrier 
selected from the group consisting of microspheres, 
liposomes, immobiliZing substrates, polymeric matrices and 
buffering agents. 
5. A method of treating peripheral neuropathy in a patient 
suffering from peripheral neuropathy comprising adminis 
tering to said patient an effective peripheral neuropathy 
treating amount of a composition having as the active agent 
a compound selected from the group consisting of 
(a) at least one compound of formula (I): 
(I) 
H O' 
/ 
C — N+ 
\ 
X Y 
Wherein: 
X is phenyl or 
—/ (OR)11 
Wherein R is H, 
and n is a Whole integer from 1 to 5; or 
Y is a tert-butyl group that can be hydroXylated or 
acetylated on one or more positions; phenyl; or 
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or Z; and 
Z is a C1 to C5 straight or branched alkyl group; or 
(b) at least one compound of formula (II) 
O 
(11) 
wherein A and B are independently CH3, CHZOH, 
CHZOW, or 
@ (OW)n, and 
Wherein n is an integer from 1 to 5, 
Z is a C1 to C5 straight or branched alkyl group; 
(c) at least one compound of formula (III): 
(III) 
Wherein 
Y is a tert-butyl group that can be hydroXylated or 
acetylated on one or more positions; phenyl or 
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wherein W is 
O O 0 || || || 10 
NH—C—Z—, —C—CH3, —C—OZ, 
or Z; and 
S=H, (OR)n, wherein R is H, 
15 
O _ || /0 
Z—C—, Z, or —CH=N+\ 
Y 
20 
Wherein Y is as de?ned above, 
n is a Whole number from 1 to 4, or 
II 25 
NH— C— Z; and 
Z is a C1 to C5 straight or branched alkyl group; 
(d) at least one other alpha-phenyl t-butyl nitrone (PBN) 
derivative selected from the group consisting of 
hydroXy PBNs, PBN esters, acetoXy PBNs, alkyl 
PBNs, alkoXy PBNs and phenyl PBNs having spin 
trapping activity in vivo in tissue; 
(e) at least one other alpha-(4-pyridyl 1-oXide)-N-tert 
butylnitrone (POBN) derivative selected from the 
group consisting of hydroXy POBNs, POBN esters, 
acetoXy POBNs, alkyl POBNs, alkoXy POBNs and 
phenyl POBNs having spin trapping activity in vivo in 
tissue; and 
(f) at least one other 5,5-dimethyl pyrroline N-oXide 
(DMPO) derivative selected from the group consisting 
of hydroXy DMPOs, DMPO esters, acetoXy DMPOs, 
alkyl DMPOs, alkoXy DMPOs and phenyl DMPOs 
having spin trapping activity in vivo in tissue; 
optionally in association With a pharmaceutically accept 
able carrier. 
6. The method of claim 5 Wherein said active agent is 
de?ned by formula 
7. The method of claim 6 Wherein X is 
8. The method of claim 6 Wherein X is 
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9. The method of claim 6 Wherein Y is a tert-butyl group 65 
that can be hydroXylated or acetylated on one or more 
positions. 
60 
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10. The method of claim 6 Wherein Y is phenyl. 
11. The method of claim 6 Wherein Y is 
12. The method of claim 5 Wherein X is 
and Y is a tert-butyl group. 
13. The method of claim 5 Wherein said active agent is 
de?ned by formula (II). 
14. The method of claim 13 Wherein A and B are selected 
from the group consisting of CH3, CHZOH and CHZOW. 
15. The method of claim 13 Wherein at least one of A and 
B is 
16. The method of claim 5 Wherein said active agent is 
de?ned by formula (III). 
17. The method of claim 16 Wherein Y is a tert-butyl 
group that can be hydroXylated or acetylated on one or more 
positions. 
18. The method of claim 16 Wherein Y is phenyl. 
19. The method of claim 16 Wherein Y is 
20. The method of claim 16 Wherein S is (OR)n. 
21. The method of claim 16 Wherein S is 
22. The method of claim 5 Wherein said active agent is 
selected from the group consisting of hydroXy PBNs, PBN 
esters, acetoXy PBNs, alkyl PBNs, alkoXy PBNs and phenyl 
PBNs. 
23. The method of claim 5 Wherein said active agent is 
selected from the group consisting of hydroXy POBNs, 
POBN esters, acetoXy POBNs, alkyl POBNs, alkoXy 
POBNs, and phenyl POBNs. 
24. The method of claim 5 Wherein said active agent is 
selected from the group consisting of hydroXy DMPOs, 
DMPO esters, acetoXy DMPOs, alkyl DMPOs, alkoXy 
DMPOs and phenyl DMPOs. 
25. A method according to claim 5 Wherein said active 
agent is PBN. 
26. A method according to claim 5 Wherein said com 
pound is provided in combination With a pharmaceutical 
carrier selected from the group consisting of microspheres, 
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liposomes, immobilizing substrates, polymeric matrices, 
and buffering agents. 
27. A method according to claim 5 Wherein said com 
pound is administered in a dosage of from 1 to 300 mg/kg 
body Weight. 
28. A method of treating intermittent claudication in a 
patient suffering from intermittent claudication comprising 
administering to said patient an effective intermittent 
claudication-treating amount of a composition having as the 
active agent a compound selected from the group consisting 
of alpha-phenyl t-butyl nitrone (PBN); 5,5-dimethyl pyrro 
line N-oXide (DMPO); alpha-(4-pyridyl 1-oXide)-N-tert 
butylnitrone (POBN) and derivatives thereof selected from 
the group consisting of hydroXy PBNs, POBNs and 
DMPOS; PBN, POBN and DMPO esters; acetoXy PBNs, 
POBNs and DMPOs; alkyl PBNs, POBNs and DMPOs; 
alkoXy PBNs, POBNs and DMPOs; and phenyl PBNs, 
POBNs and DMPOs having spin trapping activity in vivo in 
tissue; and 
a pharmaceutically acceptable carrier therefor. 
29. The method of claim 28 Wherein the active agent is 
PBN. 
30. The method of claim 28 Wherein the active agent is 
provided in a dosage of betWeen 1 to 300 mg/kg body 
Weight. 
31. The method of claim 28 Wherein the active agent is 
provided in combination With a pharmaceutical carrier 
selected from the group consisting of microspheres, 
liposomes, immobiliZing substrates, polymeric matrices and 
buffering agents. 
32. A method of treating intermittent claudication in a 
patient suffering from intermittent claudication comprising 
administering to said patient an effective intermittent 
claudication-treating amount of a composition having as the 
active agent a compound selected from the group consisting 
of 
(a) at least one compound of formula (I): 
(I) 
H O' 
/ 
C = N+ 
\ 
X Y 
Wherein: 
X is phenyl or 
—/(OR)11> 
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and n is a Whole integer from 1 to 5; or 
Y is a tert-butyl group that can be hydroXylated or 
acetylated on one or more positions; phenyl; or 
-——/OW; 
\ / 
Wherein W is 
o o 0 || || H 
or Z; and 
Z is a C1 to C5 straight or branched alkcyl group; or 
(b) at least one compound of formula (II): 
.13 N 
B 
<11) 
Wherein A and B are independently CH3, CHZOH, 
CHZOW, or 
(OW)n, 
and 
Wherein n is an integer from 1 to 5, 
W is 
O O 0 
or Z; 
Z is a C1 to C5 straight or branched alkyl group; 
(c) at least one compound of formula (III): 
(III) 
HC 
/ | 
{Q 
E 
Wherein 
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Y is a tert-butyl group that can be hydroXylated or 
acetylated on one or more positions; phenyl or 
Wherein Y is as de?ned above, 
n is a Whole number from 1 to 4, or 
Z is a C1 to C5 straight or branched alkyl group; 
(d) at least one other alpha-phenyl t-butyl nitrone (PBN) 
derivative selected from the group consisting of 
hydroXy PBNs, PBN esters, acetoXy PBNs, alkyl 
PBNs, alkoXy PBNs and phenyl PBNs having spin 
trapping activity iln vivo in tissue; 
(e) at least one other alpha-(4-pyridyl 1-oXide)-N-tert 
butylnitrone (POBN) derivative selected from the 
group consisting of hydroXy POBNs, POBN esters, 
acetoXy POBNs, alkyl POBNs, alkoXy POBNs and 
phenyl POBNs having spin trapping activity in vivo in 
tissue; and 
(f) at least one other 5,5-dimethyl pyrroline N-oXide 
(DMPO) derivative selected from the group consisting 
of hydroXy DMPOs, DMPO esters, acetoXy DMPOS, 
alkyl DMPOs, alkoXy DMPOs and phenyl DMPOs 
having spin trapping activity in vivo in tissue; 
optionally in association With a pharmaceutically accept 
able carrier. 
33. The method of claim 32 Wherein said active agent is 
de?ned by formula 
34. The method of claim 33 Wherein X is 
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35. The method of claim 33 Wherein X is 
36. The method of claim 33 Wherein Y is a tert-butyl 
group that can be hydroXylated or acetylated on one or more 
positions. 
37. The method of claim 33 Wherein Y is phenyl. 
38. The method of claim 33 Wherein Y is 
39. The method of claim 32 Wherein X is 
and Y is a tert-butyl group. 
40. The method of claim 32 Wherein said active agent is 
de?ned by formula (II). 
41. The method of claim 40 Wherein A and B are selected 
from the group consisting of CH31, CHZOH and CHZOW. 
42. The method of claim 40 Wherein at least one of A and 
B is 
@ (OW)n. 
43. The method of claim 32 Wherein said active agent is 
de?ned by formula (III). 
44. The method of claim 43 Wherein Y is a tert-butyl 
group that can be hydroXylated or acetylated on one or more 
positions. 
45. The method of claim 43 Wherein Y is phenyl. 
46. The method of claim 43 Wherein Y is 
47. The method of claim 43 Wherein S is (OR)n. 
48. The method of claim 43 Wherein S is 
49. The method of claim 42 Wherein said active agent is 
selected from the group consisting of hydroXy PBNs, PBN 
esters, acetoXy PBNs, alkyl PBNs, alkoXy PBNs and phenyl 
PBNs. 
50. The method of claim 42 Wherein said active agent is 
selected from the group consisting of hydroXy POBNs, 
POBN esters, acetoXy POBNs, alkyl POBNs, alkoXy 
POBNs, and phenyl POBNs. 
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51. The method of claim 42 wherein said active agent is 
selected from the group consisting of hydroXy DMPOS, 
DMPO esters, acetoXy DMPOS, alkyl DMPOS, alkoXy 
DMPOs and phenyl DMPOs. 
52. A method according to claim 42 Wherein said active 
agent is PBN. 
53. A method according to claim 42 Wherein said com 
pound is provided in combination With a pharmaceutical 
carrier selected from the group consisting of microspheres, 
liposomes, immobilizing substrates, polymeric matrices, 
and buffering agents. 
54. A method according to claim 42 Wherein said com 
pound is administered in a dosage of from 1 to 300 mg/kg 
body Weight. 
55. A method of treating exercise-induced muscle damage 
in a patient suffering from exercise-induced muscle damage 
comprising administering to said patient an effective 
exercise-induced muscle damage treating amount of a com 
position having as the active agent a compound selected 
from the group consisting of alpha-phenyl t-butyl nitrone 
(PBN); 5,5-dimethyl pyrroline N-oXide (DMPO); alpha-(4 
pyridyl 1-oXide)-N-tert-butylnitrone (POBN) and deriva 
tives thereof selected from the group consisting of hydroXy 
PBNs, POBNs and DMPOs; PBN, POBN and DMPO esters; 
acetoXy PBNs, POBNs and DMPOs; alkyl PBNs, POBNs 
and DMPOs; alkoXy PBNs, POBNs and DMPOS; and 
phenyl PBNs, POBNs and DMPOs having spin trapping 
activity in vivo in tissue; and 
a pharmaceutically acceptable carrier therefor. 
56. The method of claim 53 Wherein the active agent is 
PBN. 
57. The method of claim 53 Wherein the active agent is 
provided in a dosage of betWeen 1 to 300 mg/kg body 
Weight. 
58. The method of claim 53 Wherein the active agent is 
provided in combination With a pharmaceutical carrier 
selected from the group consisting of microspheres, 
liposomes, immobiliZing substrates, polymeric matrices and 
buffering agents. 
59. A method of treating exercise-induced muscle damage 
in a patient suffering from exercise-induced muscle damage 
comprising administering to said patient an effective 
exercise-induced muscle damage treating amount of a com 
position having as the active agent a compound selected 
from the group consisting of 
(a) at least one compound of formula (I): 
(I) 
H O 
\C= N/ / +\ 
X Y 
Wherein: 
X is phenyl or 
—/ (OR)n> 
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Wherein R is H, 
O 
H /O_ 
—Z—C—, or Z; or —CH=NJr 
\Y 
and n is a Whole integer from 1 to 5; or 
Y is a tert-butyl group that can be hydroXylated or 
acetylated on one or more positions; phenyl; or 
— OW; / 
Wherein W is 
O O 0 || || || 
C—CH3, NH-C-Z, C-OZ, 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group; or 
(b) at least one compound of formula (II): 
.13 N 
B i 
(11) 
wherein A and B are independently CH3, CHZOH, 
CHZOW, or 
@(OW)W and 
Wherein n is an integer from 1 to 5, 
W is 
O O O 
or Z; 
Z is a C1 to C5 straight or branched alkyl group; 
6,107,315 
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(c) at least one compound of formula (III): 
(III) 
04-2 
wherein 15 
Y is a tert-butyl group that can be hydroXylated or 
acetylated on one or more positions; phenyl or 
Wherein W is 
Wherein Y is as de?ned above, 
n is a Whole number from 1 to 4, or 
Z is a C1 to C5 straight or branched alkyl group; 
(d) at least one other alpha-phenyl t-butyl nitrone (PBN) 
derivative selected from the group consisting of 
hydroXy PBNs, PBN esters, acetoXy PBNs, alkyl 
PBNs, alkoXy PBNs and phenyl PBNs having spin 
trapping activity in vivo in tissue; 
(e) at least one other alpha-(4-pyridyl 1-oXide)-N-tert 
butylnitrone (POBN) derivative selected from the 
group consisting of hydroXy POBNs, POBN esters, 
acetoXy POBNs, alkyl POBNs, alkoXy POBNs and 
phenyl POBNs having spin trapping activity in vivo in 
tissue; and 
(f) at least one other 5,5-dimethyl pyrroline N-oXide 
(DMPO) derivative selected from the group consisting 
of hydroXy DMPOs, DMPO esters, acetoXy DMPOs, 
alkyl DMPOs, alkoXy DMPOs and phenyl DMPOs 
having spin trapping activity in vivo in tissue; 
optionally in association With a pharmaceutically accept 
able carrier. 
60. The method of claim 59 Wherein said active agent is 
de?ned by formula 
24 
61. The method of claim 60 Wherein X is 
(ORL. 
5 Q ' 
62. The method of claim 60 Wherein X is 
63. The method of claim 60 Wherein Y is a tert-butyl 
group that can be hydroXylated or acetylated on one or more 
positions. 
64. The method of claim 60 Wherein Y is phenyl. 
65. The method of claim 60 Wherein Y is 
o” 
66. The method of claim 59 Wherein X is 
10 
25 
0 
@wt. 
and Y is a tert-butyl group. 
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67. The method of claim 59 Wherein said active agent is 
de?ned by formula (II). 
68. The method of claim 67 Wherein A and B are selected 
40 from the group consisting of CH3, CHZOH and CHZOW. 
69. The method of claim 67 Wherein at least one of A and 
B is 
@ (OW)11 
70. The method of claim 59 Wherein said active agent is 
de?ned by formula (III). 
45 
71. The method of claim 70 Wherein Y is a tert-butyl 
group that can be hydroXylated or acetylated on one or more 
55 . . 
positions. 
72. The method of claim 70 Wherein Y is phenyl. 
73. The method of claim 70 Wherein Y is 
74. The method of claim 70 Wherein S is (OR)n. 
65 
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75. The method of claim 70 wherein S is 
76. The method of claim 59 Wherein said active agent is 
selected from the group consisting of hydroXy PBNs, PBN 
esters, acetoXy PBNs, alkyl PBNs, alkoXy PBNs and phenyl 
PBNs. 
77. The method of claim 59 Wherein said active agent is 
selected from the group consisting of hydroXy POBNs, 
POBN esters, acetoXy POBNs, alkyl POBNs, alkoXy 
POBNs, and phenyl POBNs. 
78. The method of claim 59 Wherein said active agent is 
selected from the group consisting of hydroXy DMPOs, 
DMPO esters, acetoXy DMPOs, alkyl DMPOs, alkoXy 
DMPOs and phenyl DMPOs. 
79. A method according to claim 59 Wherein said active 
agent is PBN. 
80. A method according to claim 59 Wherein said com 
pound is provided in combination With a pharmaceutical 
carrier selected from the group consisting of microspheres, 
liposomes, immobilizing substrates, polymeric matrices, 
and buffering agents. 
81. A method according to claim 59 Wherein said com 
pound is administered in a dosage of from 1 to 300 mg/kg 
body Weight. 
82. A method of inhibiting in?ammation arising from 
viral infection in a patient suffering from in?ammation 
arising from viral infection comprising administering to said 
patient an effective in?ammation-inhibiting amount of a 
composition having as the active agent a compound selected 
from the group consisting of alpha-phenyl t-butyl nitrone 
(PBN); 5,5-dimethyl pyrroline N-oXide (DMPO); alpha-(4 
pyridyl 1-oXide)-N-tert-butylnitrone (POBN) and deriva 
tives thereof selected from the group consisting of hydroXy 
PBNs, POBNs and DMPOs; PBN, POBN and DMPO esters; 
acetoXy PBNs, POBNs and DMPOS; alkyl PBNs, POBNs 
and DMPOs; alkoXy PBNs, POBNs and DMPOs; and phe 
nyl PBNs, POBNs and DMPOs having spin trapping activity 
in vivo in tissue; and 
a pharmaceutically acceptable carrier therefor. 
83. The method of claim 82 Wherein the active agent is 
PBN. 
84. The method of claim 82 Wherein the active agent is 
provided in a dosage of betWeen 1 to 300 mg/kg body 
Weight. 
85. The method of claim 82 Wherein the active agent is 
provided in combination With a pharmaceutical carrier 
selected from the group consisting of microspheres, 
liposomes, immobiliZing substrates, polymeric matrices and 
buffering agents. 
86. A method of inhibiting in?ammation arising from 
viral infection in a patient suffering from in?ammation 
arising from viral infection comprising administering to a 
patient an effective in?ammation-inhibiting amount of a 
composition having as the active agent a compound selected 
from the group consisting of 
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(a) at least one compound of formula (I): 
(I) 
H C=N4O 
\ 
X Y 
Wherein: 
X is phenyl or 
—/(OR)n 
Wherein R is H, 
and n is a Whole integer from 1 to 5; or 
Y is a tert-butyl group that can be hydroXylated or 
acetylated on one or more positions; phenyl; or 
Wherein W is 
O O 0 
II II II 
C—CH3, NH—C—Z, C—OZ, 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group; or 
(b) at least one compound of formula (II): 
.13 N 
B i 
(11) 
wherein A and B are independently CH3, CHZOH, 
CHZOW, or 
O/ (OW)n, 
and 
Wherein n is an integer from 1 to 5, 
6,107,315 
Z is a C1 to C5 straight or branched alkyl group; 
(c) at least one compound of formula (III): 
(III) 
04-2 
Wherein 
Y is a tert-butyl group that can be hydroXylated or 
acetylated on one or more positions; phenyl or 
Wherein W is 
Wherein Y is as de?ned above, 
n is a Whole number from 1 to 4, or 
Z is a C1 to C5 straight or branched alkyl group; 
(d) at least one other alpha-phenyl t-butyl nitrone (PBN) 
derivative selected from the group consisting of 
hydroXy PBNs, PBN esters, acetoXy PBNs, alkyl 
PBNs, alkoXy PBNs and phenyl PBNs having spin 
trapping activity in vivo in tissue; 
(e) at least one other alpha-(4-pyridyl 1-oXide)-N-tert 
butylnitrone (POBN) derivative selected from the 
group consisting of hydroXy POBNs, POBN esters, 
acetoXy POBNs, alkyl POBNs, alkoXy POBNs and 
phenyl POBNs having spin trapping activity in vivo in 
tissue; and 
(f) at least one other 5,5-dimethyl pyrroline N-oXide 
(DMPO) derivative selected from the group consisting 
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of hydroXy DMPOs, DMPO esters, acetoXy DMPOs, 
alkyl DMPOs, alkoXy DMPOs and phenyl DMPOs 
having spin trapping activity in vivo in tissue; 
optionally in association With a pharmaceutically accept 
able carrier. 
87. The method of claim 86 Wherein said active agent is 
de?ned by formula 88. The method of claim 87 Wherein X is 
89. The method of claim 87 Wherein X is 
0 || 
90. The method of claim 87 Wherein Y is a tert-butyl 
group that can be hydroXylated or acetylated on one or more 
positions. 
91. The method of claim 87 Wherein Y is phenyl. 
92. The method of claim 87 Wherein Y is 
93. The method of claim 86 Wherein X is 
and Y is a tert-butyl group. 
94. The method of claim 86 Wherein said active agent is 
de?ned by formula (II). 
95. The method of claim 94 Wherein A and B are selected 
from the group consisting of CH3, CHZOH and CHZOW. 
96. The method of claim 94 Wherein at least one of A and 
B is 
Q 
97. The method of claim 86 Wherein said active agent is 
de?ned by formula (III). 
98. The method of claim 97 Wherein Y is a tert-butyl 
group that can be hydroXylated or acetylated on one or more 
positions. 
99. The method of claim 97 Wherein Y is phenyl. 
100. The method of claim 97 Wherein Y is 
101. The method of claim 97 Wherein S is (OR)n. 



